Context Capital Management
KPTI icon

Context Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History

Context Capital Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$322K Buy
+263,696
New +$1.08M 0.01% 262
2026
Q1 		– Sell
-62,995
Closed -$464K – 395
2025
Q4 		$464K Buy
+62,995
New +$385K 0.01% 199

Other funds holding KPTI

STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
StoneX Group
StoneX Group New York $2.75B AUM 24.25% 1-Year Est. Return
TD Waterhouse Canada
TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Owl Creek Wealth Partners
Owl Creek Wealth Partners Denver, Colorado $355M AUM
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return

Context Capital Management's KPTI Position: Q3 2026 in Review

Context Capital Management opened a new position in Karyopharm Therapeutics (KPTI) in Q3 2026: 263,696 shares worth $322K. The stake represents 0.01% of the portfolio and ranks #262 among its holdings. This is a return to the name: Context Capital Management previously reported a position in KPTI as recently as Q4 2025.

Context Capital Management first reported a position in KPTI in Q4 2025 and has held it in 2 quarters since. The position peaked at $464K in Q4 2025. 18 funds tracked by Wall St. Rank hold KPTI as of Q3 2026.

  • Context Capital Management held 263,696 shares of Karyopharm Therapeutics worth $322K as of Q3 2026.
  • Karyopharm Therapeutics was a new Context Capital Management position in Q3 2026.
  • Karyopharm Therapeutics made up 0.01% of Context Capital Management's portfolio in Q3 2026, its #262 holding.
  • Context Capital Management first reported a position in Karyopharm Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Context Capital Management's Karyopharm Therapeutics position peaked at $464K in Q4 2025.
  • 18 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2026.

Based on Context Capital Management's 13F filing for Q3 2026, filed 4 Nov 2026.